Search PeptideClear
Peptides, vetted UK sellers, or GLP-1 clinics. Pick a tab below.
Try a quick search
We have not vetted that site yet.
PeptideClear can audit this source for you for free. Editorial verdict within 72 hours.
Got it. Editorial verdict within 72 hours.
We will email you a link to the published /retailer/[slug]/ profile once the audit lands.
While you wait, 3 already-vetted alternatives
Alternatives are matched to your stated goal. We earn nothing if you click through, and the links carry no tracking. How we are funded.
Longevity · NAD+ UK 2026
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last reviewed: 2026-06-12
NAD+ (nicotinamide adenine dinucleotide) is a co-enzyme that sits at the centre of cellular energy metabolism. Cellular NAD+ levels decline with age in mammalian tissues, which is the mechanism most longevity-clinic marketing builds on. UK routes split between intravenous NAD+ at private wellness clinics, oral supplements sold as food supplements, and precursor compounds (NMN and NR) which the body converts into NAD+. None of these are licensed medicines in the UK; ingestible forms fall under UK food-supplement regulation, IV and injection forms sit outside that regime as private clinical services. PeptideClear is editorial. We compare on price and evidence. We do not sell, prescribe, or take payment for placement.
NMN precursor sub-hubNAD+ in the UK shows up in five forms. IV NAD+ at private wellness clinics. Subcutaneous or intramuscular NAD+ injection courses. Oral NAD+ supplements as capsule, lozenge or powder. NMN precursor as a food supplement. NR (nicotinamide riboside, often Niagen-branded) as a food supplement. Ingestible forms are regulated as food supplements; IV and injection forms sit outside UK medicines licensing as private wellness services. The preclinical evidence base for raising NAD+ is largely animal and in-vitro; published human RCTs are limited and route-dependent. None of the routes is a UK licensed medicine.
Each route uses a different mechanism to attempt to raise systemic NAD+ levels. The regulation, cost and evidence base differ.
Clinic-administered. Not a UK licensed medicine.
Intravenous NAD+ delivered at private wellness or longevity clinics in the UK. Sessions typically run several hours and are repeated as a course. Sits outside UK medicines licensing; offered as a private wellness service.
Compounded private clinic route.
Some UK longevity clinics offer NAD+ as an injection rather than an IV. Compounded by the clinic pharmacy. Sits outside UK medicines licensing in the same way as IV NAD+; private wellness framing applies.
Food supplement. UK FSA regulated.
NAD+ sold as a capsule, lozenge or powder under the Food Supplements (England) Regulations. Marketed without medicinal claims. Bioavailability of intact oral NAD+ is debated; many brands use precursors instead.
Food supplement. Regulatory status in flux.
Nicotinamide mononucleotide. A direct NAD+ precursor. UK and EU food-supplement status has shifted across 2023 to 2026; current UK availability is via Food Supplements regulation as a registered product.
Food supplement. Niagen branded form most common.
A NAD+ precursor with a more settled supplement-regulation history than NMN. Sold in the UK as a food supplement and stocked at the larger health retailers.
The case for raising cellular NAD+ in older animals rests on a substantial preclinical literature. Rodent studies show that NAD+ precursors raise tissue NAD+ levels and shift several age-associated metabolic markers. Whether those shifts translate to clinically meaningful outcomes in humans is the question that current trials are designed to answer; results so far are partial and dose-, route- and population-dependent.
Oral NAD+ itself is poorly absorbed intact; most ingested NAD+ is broken down in the gut. That is one reason the supplement industry centres on precursor compounds (NMN and NR), which are absorbed differently and convert to NAD+ inside cells. IV NAD+ bypasses that absorption question by routing the molecule directly into the bloodstream; what remains debated is how much reaches and persists in target tissue.
For UK readers, the practical point is that the IV, injection and supplement routes are not interchangeable on cost, regulation or evidence. The longevity sub-hubs on this site cover each route at the depth required to make a route-by-route call. They do not recommend a specific brand or protocol.
Oral NAD+, NMN and NR sold without medicinal claims sit under the Food Supplements (England) Regulations 2003. Labelling, permitted health claims and maximum daily amounts are governed accordingly. NMN specifically has been the subject of regulatory back-and-forth across the UK, EU and US since 2022; current UK availability has stabilised under the food-supplement frame.
IV NAD+ and NAD+ injection courses delivered at private clinics are not regulated as medicines because they are not marketed under a Marketing Authorisation. They sit under private clinical service regulation: the clinic must hold appropriate CQC registration in England (or equivalent in the devolved nations), the prescribing practitioner must be GMC- or GPhC-registered, and the compounding pharmacy (if separate) must be GPhC-registered.
We do not name specific UK IV NAD+ clinics on this hub. The clinic landscape changes faster than the editorial cycle can verify. Articles under this hub may name verified clinics at the time of editorial review.
Also on PeptideClear
Cosmetic peptides
UK skincare with GHK-Cu, Matrixyl
If you also care about topical peptide skincare, the cosmetic peptides hub compares UK serums and creams on declared INCI position.
VisitCollagen
Marine, bovine, vegan compared
If you also care about ingestible collagen, the hub compares UK brands on type, sourcing, kDa and dose per serving.
VisitGLP-1 clinics
UK clinics ranked
If you also care about prescription GLP-1 routes, the clinics hub compares UK high-touch operators on GPhC, GMC and price.
VisitPeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). PeptideClear's editorial and publishing operation is delivered by Best Business Loans Ltd.
Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.
Operates under UK data protection and consumer standards, including UK GDPR.
Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.